Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
RAPID: PET/MRI for Prostate Cancer Diagnosis
NCT02659527Phase 3Completed
- Sponsor
- Medical University of Vienna
- Start
- Jan 2016
- Primary completion
- May 2022
- Modality
- Peptide-Drug Conjugates
- Countries
- 1
01
Overview
A Phase 3 trial of gallium ga-68 gozetotide in prostate cancer (PCa), sponsored by Medical University of Vienna. Started Jan 2016; status: completed.
02
Drugs
gallium ga-68 gozetotide
03
Conditions
prostate cancer (PCa)
Beyond the preview
Go deeper on NCT02659527.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02659527.